Stockscreener 앱 받기
584.79
3.78%
21.30
United Therapeutics Corp 주식(UTHR)의 최신 뉴스
United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance
United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance
United Therapeutics opens third xenograft production facility - Investing.com
A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance
United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria
After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Is Liquidia Stock Skyrocketing Wednesday?United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
A $10M payment is also due from United Therapeutics (UTHR) in its settlement with Liquidia. - Stock Titan
Liquidia shares surge to 5-month high premarket on United Therapeutics settlement - Yahoo Finance
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
0.16%
자본화:
|
볼륨(24시간):